Novel Targeted Therapy for Precursor B Cell Acute Lymphoblastic Leukemia: Anti-CD22 Antibody-MXD3 Antisense Oligonucleotide Conjugates

被引：0
|
作者：
Satake, Noriko [1 ]
Duong, Connie [1 ]
Oestergaard, Michael [2 ]
Yoshida, Sakiko [1 ]
Chen, Cathy [1 ]
Nolta, Jan A. [3 ]
Guo, Shuling [4 ]
Seth, Punit [2 ]
Nitin, Nitin [5 ]
Tuscano, Joseph [6 ]
机构：
[1] Univ Calif Davis, Sacramento, CA USA
[2] ISIS, Carlsbad, CA USA
[3] Univ Calif Davis, Sacramento, CA 95817 USA
[4] Isis Pharmaceut Inc, Carlsbad, CA USA
[5] Univ Calif Davis, Davis, CA USA
[6] Univ Calif Davis, Ctr Canc, Sacramento, CA USA
来源：
BLOOD | 2014年 / 124卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [41] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Sisi Wang
    Lijun Peng
    Wenqian Xu
    Yuebo Zhou
    Ziyan Zhu
    Yushan Kong
    Stewart Leung
    Jin Wang
    Xiaoqiang Yan
    Jian-Qing Mi
    Frontiers of Medicine, 2022, 16 : 139 - 149
  • [42] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Wang, Sisi
    Peng, Lijun
    Xu, Wenqian
    Zhou, Yuebo
    Zhu, Ziyan
    Kong, Yushan
    Leung, Stewart
    Wang, Jin
    Yan, Xiaoqiang
    Mi, Jian-Qing
    FRONTIERS OF MEDICINE, 2022, 16 (01) : 139 - 149
  • [43] Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecific antibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic leukemia
    Wang Sisi
    Peng Lijun
    Xu Wenqian
    Zhou Yuebo
    Zhu Ziyan
    Kong Yushan
    Leung Stewart
    Wang Jin
    Yan Xiaoqiang
    Mi JianQing
    Frontiers of Medicine, 2022, 16 (01) : 139 - 149
  • [44] MCL-1 Inhibition Overcomes Anti-apoptotic Adaptation to Targeted Therapies in B-Cell Precursor Acute Lymphoblastic Leukemia
    Manzano-Munoz, Albert
    Alcon, Clara
    Menendez, Pablo
    Ramirez, Manuel
    Seyfried, Felix
    Debatin, Klaus-Michael
    Meyer, Luder H.
    Samitier, Josep
    Montero, Joan
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2021, 9
  • [45] A NOVEL ANTI-CD22 IMMUNOTOXIN, MOXETUMOMAB PASUDOTOX (HA22, CAT-8015): ACTIVITY IN PEDIATRIC PATIENTS WITH RELAPSED ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (SCT)
    Shah, N. N.
    Bhojwani, D.
    Silverman, L. B.
    Whitlock, J. A.
    Richards, K.
    Stetler-Stevenson, M.
    Buzoianu, M.
    Ibrahim, R.
    Pastan, I
    Wayne, A. S.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S234 - S234
  • [46] Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models
    Ruella, Marco
    Maude, Shannon L.
    Engels, Boris
    Barrett, David M.
    Frey, Noelle
    Marcucci, Katherine T.
    Shestova, Olga
    Singh, Nathan
    Perazzelli, Jessica
    Christian, David A.
    Haagen, Dana
    Lacey, Simon F.
    Melenhorst, J. Joseph
    Brogdon, Jennifer
    Young, Regina M.
    Porter, David L.
    June, Carl H.
    Grupp, Stephan A.
    Gill, Saar I.
    BLOOD, 2017, 130
  • [47] Understanding IKZF1 gene regulation for targeted therapy to improve prognosis and treatment of patients with B cell precursor acute lymphoblastic leukemia
    Heydt, Q.
    Morel, G.
    Simand, C.
    Kastner, P.
    Chan, S.
    Heizmann, B.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2023, 53 : 303 - 303
  • [48] Doxorubicin-Loaded Platelets Conjugated with Anti-CD22 Mabs: A Novel Targeted Delivery System for B-Cell Lymphoma Treatment with Cardiac Avoidance
    Xu, Peipei
    Zuo, Huaqin
    Zhou, Rong-Fu
    Ouyang, Jian
    Chen, Bing
    BLOOD, 2017, 130
  • [49] Inotuzumab ozogamicin: a CD22 mAb-drug conjugate for adult relapsed or refractory B-cell precursor acute lymphoblastic leukemia
    Yurkiewicz, Ilana R.
    Muffly, Lori
    Liedtke, Michaela
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2018, 12 : 2293 - 2300
  • [50] Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia
    Patricia K. Grüninger
    Franziska Uhl
    Heike Herzog
    Gaia Gentile
    Marta Andrade-Martinez
    Tobias Schmidt
    Kyuho Han
    David W. Morgens
    Michael C. Bassik
    Michael L. Cleary
    Oliver Gorka
    Robert Zeiser
    Olaf Groß
    Jesús Duque-Afonso
    Cancer Gene Therapy, 2022, 29 : 1751 - 1760
12345